Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysisResearch in context

Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysisResearch in context

Summary: Background: Enzalutamide was approved for high-risk biochemically recurrent (hrBCR) prostate cancer based on the EMBARK trial (NCT02319837; 17 December 2014–31 January 2023). In EMBARK, treatment was suspended at week 37 if prostate-specific antigen (PSA) was <0.2 ng/mL and reinstated i...

Full description

Saved in:
Bibliographic Details
Main Authors: Stephen J. Freedland, Ugo De Giorgi, Antti Rannikko, Fred Saad, Miguel Ramirez-Backhaus, Anchen F. Nasr, Jasmina I. Ivanova, Arijit Ganguli, Pavol Kral, Arlene L. Reisman, Neal D. Shore
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:EClinicalMedicine
Subjects:
Enzalutamide
Quality of life
MMRM analysis
Patient-reported outcomes
Online Access:http://www.sciencedirect.com/science/article/pii/S258953702500361X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S258953702500361X

Similar Items